JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications.
Saved in:
| Title: | JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications. |
|---|---|
| Authors: | Russell MD; Centre for Rheumatic Diseases, King's College London, London, UK mark.russell@kcl.ac.uk., Stovin C; Centre for Rheumatic Diseases, King's College London, London, UK., Alveyn E; Centre for Rheumatic Diseases, King's College London, London, UK., Adeyemi O; Centre for Rheumatic Diseases, King's College London, London, UK., Chan CKD; Centre for Rheumatic Diseases, King's College London, London, UK., Patel V; Centre for Rheumatic Diseases, King's College London, London, UK., Adas MA; Centre for Rheumatic Diseases, King's College London, London, UK., Atzeni F; Rheumatology Unit, University of Messina, Messina, Italy., Ng KKH; Department of Medical Oncology, University College London, London, UK., Rutherford AI; Centre for Rheumatic Diseases, King's College London, London, UK., Norton S; Centre for Rheumatic Diseases, King's College London, London, UK., Cope AP; Centre for Rheumatic Diseases, King's College London, London, UK., Galloway JB; Centre for Rheumatic Diseases, King's College London, London, UK. |
| Source: | Annals of the rheumatic diseases [Ann Rheum Dis] 2023 Aug; Vol. 82 (8), pp. 1059-1067. Date of Electronic Publication: 2023 May 29. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't; Network Meta-Analysis |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 0372355 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-2060 (Electronic) Linking ISSN: 00034967 NLM ISO Abbreviation: Ann Rheum Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
